ADHERENCE AND PERSISTENCE AMONG HEREDITARY ANGIOEDEMA PATIENTS TREATED WITH BEROTRALSTAT, LANADELUMAB, AND SUBCUTANEOUS PLASMA-DERIVED C1-INHIBITOR

Berotralstat is a novel, targeted oral long-term prophylactic (LTP) treatment for hereditary angioedema (HAE). Real-world evidence comparing WAO/EAACI recommended first-line HAE LTP therapies is limited. We investigated adherence and persistence following initiation of berotralstat, lanadelumab, and subcutaneous plasma-derived C1-inhibitor (SC-pdC1-INH).